Artivion (NYSE:AORT) Downgraded to "Hold" Rating by Wall Street Zen

Key Points

• Wall Street Zen downgraded Artivion from "buy" to "hold", though seven analysts still rate the stock a Buy and the consensus price target is $51 with an overall "Moderate Buy" rating.
• Artivion beat Q results with $0.17 EPS versus $0.14 expected and revenue of $118.3M (up 19.2% YoY); shares were trading around $37.74 with a market cap of $1.83B and a 52‑week range of $23.04–$48.25.

Artivion (NYSE:AORT - Get Free Report) was downgraded by stock analysts at Wall Street Zen from a "buy" rating to a "hold" rating in a report issued on Saturday.

A number of other research analysts also recently issued reports on the company. Weiss Ratings raised Artivion from a "sell (d)" rating to a "hold (c-)" rating in a report on Friday, February 20th. Needham & Company LLC restated a "buy" rating on shares of Artivion in a research report on Monday. Canaccord Genuity Group dropped their price target on Artivion from $51.00 to $48.00 and set a "buy" rating for the company in a research report on Friday, February 13th. LADENBURG THALM/SH SH upgraded Artivion from a "neutral" rating to a "buy" rating and set a $42.00 price target for the company in a research report on Friday, April 10th. Finally, Stifel Nicolaus set a $55.00 price target on Artivion in a research report on Thursday, March 5th. Seven research analysts have rated the stock with a Buy rating and one has given a Hold rating to the company's stock. According to data from MarketBeat, Artivion presently has an average rating of "Moderate Buy" and a consensus price target of $51.00.

Artivion Price Performance

Shares of NYSE AORT opened at $37.74 on Friday. The company has a debt-to-equity ratio of 0.49, a quick ratio of 2.62 and a current ratio of 3.53. The company has a market cap of $1.83 billion, a PE ratio of 188.72 and a beta of 1.63. The business has a 50-day simple moving average of $36.69 and a two-hundred day simple moving average of $41.44. Artivion has a fifty-two week low of $23.04 and a fifty-two week high of $48.25.

Artivion (NYSE:AORT - Get Free Report) last released its earnings results on Thursday, February 12th. The company reported $0.17 EPS for the quarter, topping analysts' consensus estimates of $0.14 by $0.03. Artivion had a return on equity of 7.43% and a net margin of 2.21%.The firm had revenue of $118.30 million during the quarter, compared to the consensus estimate of $116.42 million. The company's revenue for the quarter was up 19.2% compared to the same quarter last year. As a group, equities analysts expect that Artivion will post 0.63 EPS for the current fiscal year.

Insider Activity at Artivion

In other Artivion news, insider John E. Davis sold 4,573 shares of the company's stock in a transaction dated Tuesday, March 3rd. The stock was sold at an average price of $37.78, for a total transaction of $172,767.94. Following the sale, the insider owned 230,794 shares in the company, valued at $8,719,397.32. This represents a 1.94% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, SVP Marshall S. Stanton sold 2,149 shares of the company's stock in a transaction dated Tuesday, March 3rd. The stock was sold at an average price of $37.78, for a total value of $81,189.22. Following the sale, the senior vice president owned 60,097 shares in the company, valued at approximately $2,270,464.66. This trade represents a 3.45% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 133,043 shares of company stock worth $4,977,158 over the last quarter. 6.30% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Artivion

Several large investors have recently bought and sold shares of AORT. Aster Capital Management DIFC Ltd increased its holdings in Artivion by 402.3% during the 3rd quarter. Aster Capital Management DIFC Ltd now owns 648 shares of the company's stock worth $27,000 after purchasing an additional 519 shares during the period. Caitong International Asset Management Co. Ltd purchased a new stake in Artivion during the 3rd quarter worth about $27,000. Rockefeller Capital Management L.P. increased its holdings in shares of Artivion by 150.0% in the 4th quarter. Rockefeller Capital Management L.P. now owns 665 shares of the company's stock valued at $30,000 after acquiring an additional 399 shares during the last quarter. Larson Financial Group LLC increased its holdings in shares of Artivion by 148.5% in the 4th quarter. Larson Financial Group LLC now owns 942 shares of the company's stock valued at $43,000 after acquiring an additional 563 shares during the last quarter. Finally, USA Financial Formulas increased its holdings in shares of Artivion by 163.5% in the 4th quarter. USA Financial Formulas now owns 1,133 shares of the company's stock valued at $52,000 after acquiring an additional 703 shares during the last quarter. Hedge funds and other institutional investors own 86.37% of the company's stock.

Artivion Company Profile

Artivion, Inc NYSE: AORT is a global medical technology company that develops, manufactures and markets implantable tissue products and surgical devices for cardiac and vascular surgery. The company’s portfolio includes biologic implants derived from human and animal tissue, such as allografts and xenografts, as well as synthetic scaffolds and surgical adhesives. These products are designed to repair, reinforce or replace damaged cardiovascular and thoracic tissues during procedures such as aortic repair, heart valve surgery and vascular reconstruction.

Originally founded in 1984 under the name CryoLife, the company rebranded as Artivion in early 2022 to reflect its broader mission in cardiovascular innovation.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.